D. Gambhire

发表

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)

Vikas G. Pai, S. Mukhopadhyay, A. Bhansali, 2014, Journal of diabetes science and technology.

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Sung-Bae Kim, E. Tokunaga, H. Rugo, 2022, New England Journal of Medicine.

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives

Vivek Subbiah, K. Kairemo, V. Subbiah, 2017, Diagnostics.

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

E. Schmidt, A. Tolcher, M. Sznol, 2017, Clinical Cancer Research.

Factors associated with early relapse to insulin dependence in unprovoked A-β+ ketosis-prone diabetes.

C. Hampe, A. Balasubramanyam, Dinakar Iyer, 2015, Journal of diabetes and its complications.

Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

N. Harbeck, D. Cameron, N. Ueno, 2023, Cancer Research.

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Sung-Bae Kim, Yeon-Hee Park, F. André, 2023, The Lancet.

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

E. Tokunaga, F. Cottone, W. Jacot, 2022, Annals of Oncology.

Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors.

E. Schmidt, A. Tolcher, M. Sznol, 2016 .